Sign in
Taking people in South KoreaPhase 2

Belzutifan for teenagers with advanced or spreading solid tumors

Tests belzutifan in adolescents with advanced solid tumors, including pheochromocytoma and paraganglioma.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Seoul, South KoreaSee the 2 sitesAlso in 7 other countries, 17 sites
Trial code
Registry title
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
Status
Recruiting
Phase
Phase 2
People taking part
15 people, planned
Started
13 Oct 2026
Expected to end
2 Jan 2034
Type of study
Interventional
Treatments tested
  • Belzutifan
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adolescents with certain solid tumors: pheochromocytoma/paraganglioma, wild-type gastrointestinal stromal tumor, or localized tumors linked to von Hippel-Lindau disease. It tests the safety of belzutifan.

Age
12 Years to 17 Years
Sex
All sexes can join.
Disease stage
Locally advanced, unresectable or metastatic pheochromocytoma/paraganglioma or wild-type gastrointestinal stromal tumor, or localized tumors linked to von Hippel-Lindau disease. The disease must be measurable per RECIST 1.1.
Earlier treatment
People who had earlier treatment with any hypoxia inducible factor-2α inhibitor, including belzutifan, cannot join.

Main reasons for not taking part

  • Pulse oximeter reading <92% at rest, or need for supplemental oxygen
  • Clinically significant cardiac disease, uncontrolled cardiac condition or congenital long QT syndrome
  • History of human immunodeficiency virus infection
  • Prior treatment with any hypoxia inducible factor-2α inhibitor, including belzutifan
  • Active infection requiring systemic therapy

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • The main inclusion criteria include but are not limited to the following:
  • Has a diagnosis of one of the following: locally advanced, unresectable, or metastatic pheochromocytoma/paraganglioma or wild-type gastrointestinal stromal tumors, or localized tumors associated with von Hippel-Lindau disease
  • Has measurable disease per RECIST 1.1

Who cannot take part

  • Has received prior treatment with any hypoxia inducible factor-2α inhibitor, including belzutifan
  • Has had an allogenic tissue/solid organ transplant
  • Has a history of human immunodeficiency virus infection
  • Has a history of autologous stem cell transplant within 6 months of start of study intervention
  • Has known additional malignancy that is progressing or has required active treatment within the past 2 years
  • Has an active infection requiring systemic therapy
  • Has clinically significant cardiac disease or electrocardiogram indicating uncontrolled cardiac condition or has congenital long QT syndrome
  • The main exclusion criteria include but are not limited to the following:
  • Has a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
  • Has known active central nervous system metastases and/or carcinomatous meningitis

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 17 years old?

Where in South Korea

Also in 7 other countries, 17 sites

  • Asan Medical Center-Pediatrics - Pedicatric Oncology (Site 5973)Seoul, South KoreaContact: Study CoordinatorTaking people
  • Seoul National University Hospital-Pediatrics (Site 5972)Seoul, South KoreaContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

Researchers are looking for new ways to treat adolescents with locally advanced, unresectable, or metastatic solid tumors. Participants were enrolled into pheochromocytoma/paraganglioma (PPGL), wild type gastrointestinal stromal tumor (wtGIST), and Von Hippel-Lindau (VHL) disease-associated localized tumors cohorts:

Read full original descriptionShow less

* PPGL are rare cancers that start in cells that make hormones in the adrenal glands * wtGIST is a less common type of cancer that starts in the digestive tract. Wild type means it does not have certain gene mutations (changes) * VHL disease-associated localized tumors are rare tumors caused by a certain gene mutation that may be passed down from parents to children * Locally advanced means the cancer has spread into nearby tissue * Unresectable means the cancer cannot be removed by surgery * Metastatic means the cancer has spread to other parts of the body

The goal of the study is to learn about the safety of belzutifan and if people tolerate it.

The group in the trial

  • BelzutifanTreatment being tested

    Participants will receive belzutifan 80 mg (body weight \<40 kg) or 120 mg (body weight ≥40 kg) orally once daily for approximately 2 years.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
LIGHTBEAM-U01 Substudy 01E: A Phase 2 Substudy to Evaluate the Safety and Efficacy of Belzutifan in Participants With Solid Tumors
Plain-language title
Belzutifan for teenagers with advanced or spreading solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07700758, who can take part
Record updated
10 November 2026